Chongqing Zhifei Biological Products Co.

About Chongqing Zhifei Biological Products Co.

Chongqing Zhifei Biological Products Co., Ltd. is the largest listed vaccine company in China,which has its presence in biological product industry in 2002.The Company achieved an operating income of RMB38.3 billion In  2022 with the support of its nearly 7000 employees.As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use. Our research channels cover many indications extensively: like COVID-19, tuberculosis, meningitis, etc.

  • CN
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Manufacturer/Innovator
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Chongqing Zhifei Biological Products Co. (5)

  • Recombinant COVID-19 Vaccine(CHO Cell)

    Product Recombinant COVID-19 Vaccine(CHO Cell)

    Zifivax is the first approved Recombinant COVID vaccine, there are more than 300million doses used worldwide.
  • Recombinant Mycobacterium Tuberculosis Fusion Protein

    Product Recombinant Mycobacterium Tuberculosis Fusion Protein

    C-TST is a new diagnose method to detect Mtb infectionfor,which uses antigen-specific (ESAT6 & CFP10) immune response, same with the principle of action used in IGRAs.(1)Suitable for Large Scale LTBI Screening; 
    (2)Non Cross-React with BCG Vaccine; 
    (3)WHO Guideline Recommended;  q...
  • semaglutide

    Product semaglutide

    we can supply the semaglutide API with a good price and good quality,we are also open for the cooperation model.
  • Meningococcal Polysaccharide Vaccine

    Product Meningococcal Polysaccharide Vaccine

    Chongqing zhifei biological products co., ltd offers a wide range of products which includes meningococcal polysaccharide vaccine. Function and use: it can be used to prevent epidemic cerebrospinal meningitis caused by meningococcus group a, c, y, and w135 infection. Contact us for more information.
  • Group A, C Meningococcal Polysaccharide-Conjugate Vaccine

    Product Group A, C Meningococcal Polysaccharide-Conjugate Vaccine

    MeningACon is the first approved product in China,more than 36 million doses has been used.

Chongqing Zhifei Biological Products Co. Resources (1)